Open AccessClinical features of secondary acute myeloid leukemia in children
Author(s) -
Ф. А. Махачева,
Т. Т. Валиев
Publication year - 2020
Publication title -
onkogematologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.118
H-Index - 3
eISSN - 2413-4023
pISSN - 1818-8346
DOI - 10.17650/1818-8346-2020-15-4-12-17
Subject(s) - medicine , oncology , myeloid leukemia , transplantation , fludarabine , cancer , leukemia , lymphoma , stem cell , chemotherapy , cyclophosphamide , biology , genetics
Background . Secondary malignancies in pediatric cancer survivors is an actual problem in modern oncopediatry. Alkylating agents and topoisomerase II inhibitors used for primary tumors treatment, induce secondary acute myeloid leukemia (sAML), which treatment results are unsatisfactory. Objective . By predicating on literature and own data to evaluate clinical and biologic features and therapeutic potential of pediatric sAML. Materials and methods . Six patients (age 7–16 years) with sAML were enrolled the study from June 1998 to December 2016. Follow up until September 2020. Primary tumors, which therapy could induce sAML were acute lymphoblastic leukemia, Burkitt lymphoma, germ cell tumor, osteosarcoma, nephroblastoma. Results and conclusion . From 6 patients, included in the study, 2 are alive (+58 and +67 months after allogenic stem cell transplantation), that match global data. Fludarabine-containing regimens and allogeneic hematopoietic stem cell transplant could be a method of choice for this unfavorable group of patients.